08.45 Chair’s Opening Address

08.55 CASE STUDY: Preparation And Structural Analysis Of Co-Crystal Phases

Pharmorphix is one of Europe’s leading providers of solid-form research services to the international pharmaceutical and biotech industries. The ability to prepare co-crystals in significant quantities is one of the major challenges that still need to be overcome in order for this field to become an economically viable method of producing new drug products. Pharmorphix laboratories investigates how both traditional and new methodologies can be employed to overcome these problems.

PLease visit www.iqpc.com/nl/cocrystals for more Details

Dr Christopher Frampton
Chief Scientific Officer
Pharmorphix

09.40 CASE STUDY: Structure Property Relationships

• Co-Crystal Definitions
• Current State Of Co-Crystal Screening
• Increasing Success And Priority Of Co-Crystal Screening
• Literature Case-Studies And Internal Company Case Studies For The Progression Over The Last 12 Months

Dr Ahmad Sheikh
Group Leader, Solid State Chemistry
Abbott Laboratories

10.55 CASE STUDY: Structure-Property Relationships In Multiple Component Crystalline Solids

The importance of structure property relationships is becoming ever more apparent in the field of co-crystals and particularly in current environments to understand the physical composition of a compound and the properties that will in turn exhibit. Mike has worked extensively in the area of Co-Crystals for a number of years but has been focusing a large part of his research in the last year in this area. With brand new case study examples this is set to be a really thought provoking talk.

For for Details on this talk please visit www.iqpc.com/nl/cocrystals

Professor Mike Zawortoko
Professor and Chairperson, Department of Chemistry
University of South Florida

11.40 Beyond Two-Component Co Crystals: Ternary Co-Crystals

• Need for ternary co-crystals
• Feasibility of manufacture
• Case-study example

Dr Peter Kaprinski
Principal Fellow and Leader of US Salt and Polymorphism and Particle Engineering networks
Novartis Pharmaceuticals

13.30 Co-Crystals And Amorphous Formulations To Significantly Increase The Bioavailability Of Insoluble Weak Bases: A Case Study In Sanofi-Aventis Discovery

• Case study results on a very insoluble weak base to improve bioavailability to facilitate its entry into development
• Discussion of a internally developed co-crystal screening methodology based on a co-former in-silico selection that uses clusterisation of co-formers
• An overview of whole methodology from the screening to the scaleup and Phys-chem and In-vivo evaluations of the obtained co-crystal will be exposed
• In addition, a summation of a amorphous API study on the same compound to help improve its bioavailability
• Analysis and comparison of the failures and successes of each approach and in-vivo results obtained from each process

Dr Jerome Menegotto
Discovery Analytics, Head of Solid State Laboratory
sanofi-aventis

14.15 The Why And How Of Co-Crystals From A Development Perspective

• When are co-crystals interesting?
• What requirements should they meet?
• What are the pitfalls?
• How can co-crystal screening be tied in the normal development process

Dr Rob Geertman
Group Head Solid State Chemistry
Organon

15.30 Round Table Discussion: Streamlining Your Development Processes

This discussion session will enable participants to discuss issues surrounding:

• Process and pre-formulation difficulties, identification and potential solution implementation
• The potential positive effects on your bottom line

16.15 Chairperson’s Closing Remarks

16.30 Close Of Conference Day Two